Significant Suppression of Angiogenetic Cytokines by Additional Short-Term Administration of Sorafenib in Transarterial Chemoembolization for Hepatocellular Carcinoma

Trial Profile

Significant Suppression of Angiogenetic Cytokines by Additional Short-Term Administration of Sorafenib in Transarterial Chemoembolization for Hepatocellular Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top